Evommune, Inc.
EVMN
$20.49
$0.301.49%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -57.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -57.14% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -57.14% |
| SG&A Expenses | 80.79% | 157.05% | 14.28% | 7.88% | 30.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.84% | 38.51% | 41.24% | -18.72% | 67.68% |
| Operating Income | -59.35% | -38.51% | 19.31% | 18.72% | -300.43% |
| Income Before Tax | -48.89% | -36.41% | 21.62% | 50.46% | -422.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.89% | -36.41% | 21.62% | 50.46% | -422.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.89% | -36.41% | 21.62% | 50.46% | -422.88% |
| EBIT | -59.35% | -38.51% | 19.31% | 18.72% | -300.43% |
| EBITDA | -61.07% | -39.33% | 19.58% | 19.11% | -320.76% |
| EPS Basic | 93.21% | 90.17% | 22.85% | 51.33% | -400.85% |
| Normalized Basic EPS | 93.21% | 89.46% | 22.85% | 51.33% | -400.83% |
| EPS Diluted | 93.21% | 90.17% | 22.85% | 51.33% | -400.85% |
| Normalized Diluted EPS | 93.21% | 89.46% | 22.85% | 51.33% | -400.83% |
| Average Basic Shares Outstanding | 2,093.49% | 1,194.06% | 1.59% | 1.78% | 4.40% |
| Average Diluted Shares Outstanding | 2,093.49% | 1,194.06% | 1.59% | 1.78% | 4.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |